AzTrials
AzTrials

Achalasia CardiaNCT04951739

To Investigate the Incidence of Reflux in Patients After Per-oral Endoscopic Myotomy in Achalasia Cardia Patients

An observational study of Achalasia Cardia and Gastroesophageal Reflux, run by Asian Institute of Gastroenterology, India at 1 site in India.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Achalasia is a rare motility disorder of the oesophagus that is characterized by aperistalsis of the oesophagal body and dysrelaxation of the lower oesophagal sphincter (LES). Current treatment is palliative, and the aim of the treatment is to diminish the obstructive function of the esophagogastric junction (EGJ). Read more about this study

Who is it for?
Ages 18 to 80 yearsHealthy volunteers can take part
Conditions the study is for
Achalasia Cardia, Gastroesophageal Reflux
What is being tested?
Peroral endoscopic myotomy
Type of treatment
Surgery or procedure
How many people
64 participants
Where
1 siteIndia
Study dates
1 Jul 2021to 15 Mar 2022
How long will I take part?
3 Months
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 80 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Study population: Treated achalasia patients with and without gastroesophageal reflux symptoms visiting the outpatient clinic of the Gastroenterology Department.

Who may be able to join

  • A- Treated achalasia patients with gastroesophageal reflux symptoms
  • Diagnosis of idiopathic achalasia confirmed by oesophageal manometry that shows the following criteria:
  • Aperistalsis or simultaneous contractions in the oesophageal body.
  • Impaired relaxation of the Lower oesophageal sphincter
  • Treatment of achalasia with per-oral endoscopic myotomy (POEM)
  • The minimum total score on the Gastroesophageal Reflux Disease Questionnaire (GERDQ) of ≥ 8.
Show all 17Show fewer
  • Gastroesophageal symptoms after treatment lasting more than three months.
  • Age 18-80 years.
  • Written informed consent.
  • B- Treated achalasia patients without gastroesophageal reflux symptoms
  • Diagnosis of idiopathic achalasia confirmed by oesophagal manometry that shows the following criteria:
  • Aperistalsis or simultaneous contractions in the oesophageal body.
  • Impaired relaxation of the Lower oesophageal sphincter
  • Treatment of achalasia with per-oral endoscopic myotomy (POEM)
  • The maximum total score on the Gastroesophageal Reflux Disease Questionnaire (GERDQ) of < 8.
  • Age 18-80 years.
  • Written informed consent.

Who cannot join

  • Pseudoachalasia.
  • Upper gastrointestinal malignancy.
  • Chagas disease.
  • Peptic ulcer disease.
  • Inability to stop PPI, H2-receptor antagonist or prokinetic drug for two weeks
  • Presence of an extremely dilated oesophagus body >5 cm

Trial locations and contacts

1 site in 1 country.

India1 site
  • AIG Hospitals

    Hyderabad, Telangana, 500032

Other trials in India

About this study

Achalasia is a rare motility disorder of the oesophagus that is characterized by aperistalsis of the oesophagal body and dysrelaxation of the lower oesophagal sphincter (LES). Current treatment is palliative, and the aim of the treatment is to diminish the obstructive function of the esophagogastric junction (EGJ). Due to this approach, the most frequent complication post-treatment is gastroesophageal reflux (GER). However, not every treated patient develops GER symptoms and the mechanism behind the occurrence of GER in treated achalasia are unclear. In this study, we aim to Investigate the incidence of reflux in patients after peroral endoscopic myotomy in patients with achalasia cardia.

Read the detailed description
  1. INTRODUCTION- Achalasia is a rare motility disorder of the oesophagus that is characterized by aperistalsis of the oesophagal body and dysrelaxation of the lower oesophagal sphincter (LES). Current treatment is palliative, and the aim of the treatment is to diminish the obstructive function of the esophagogastric junction (EGJ). Due to this approach, the most frequent complication post-treatment is gastroesophageal reflux (GER). However, not every treated patient develops GER symptoms and the mechanism behind the occurrence of GER in treated achalasia are unclear. In this study, we aim to Investigate the incidence of reflux in patients after peroral endoscopic myotomy in patients with achalasia cardia.
  2. STUDY OBJECTIVES Our hypothesis is those gastroesophageal reflux symptoms in treated patients with achalasia are dependent on retention and fermentation of food due to a reduced clearance by aperistalsis of the oesophageal body rather than the result of actual acid reflux episodes. We expect a difference in gastroesophageal reflux episodes, LES pressure in the treated patients with achalasia that experience gastroesophageal reflux symptoms compared to the the group that does not encounter gastroesophageal reflux symptoms.
  3. STUDY POPULATION This observational study has a prospective design. Two groups of study subjects will be included. Treated patients with achalasia with gastroesophageal reflux symptoms and treated patients with achalasia without gastroesophageal reflux symptoms. On the baseline, clinical data will be collected regarding medical history, family history and medical symptoms related to GER or achalasia.In all the included study subjects, several measurements will be done at AIG hospitals, Hyderabad. The duration of the study is dependent on the rate of inclusion of the study subjects but, it is expected that in 6 months, all study subjects will be included.
  4. DESIGN AND DURATION OF THE STUDY- It will be a prospective observational study for 6 months.
  5. METHODOLOGY

5a. SUBJECT RECRUITMENT - Treated patients with idiopathic achalasia visiting the outpatient clinic will be asked to participate in the study. Only when a study subject has given informed consent, questionnaires concerning demographic and clinical data will be recorded, and measurements will be performed.

5b. RANDOMIZATION AND BLINDING- NO

5c. STUDY METHODS-

5d.STUDY PROCEDURE-

Baseline clinical data will be collected using different questionnaires. The participant will be subjected to the GERD Questionnaire to be sure that he or she is allocated to the correct study group. For this study, all included study subjects will undergo a few measurements. Upper GI endoscopy under conscious sedation will be done, followed by a timed barium oesophagogram \&. High-resolution manometry will be done. The barium oesophagography is performed to gain insight into oesophageal emptying and the width of the oesophagus. After peroral endoscopic myotomy has been done, these measurements, including upper GI endoscopy, 24 hours ambulatory pH and impedance testing, High-resolution oesophageal manometry \& Timed barium oesophagogram, will be done at 3 months of follow-up.

5e. Study requirements and timeline

The measurements will be performed after cessation of PPIs, H2-antagonists and medications that can influence intestinal motility for one week. To reduce severe symptoms, patients are allowed to take rescue medication in the form of antacids. Furthermore, one day before the measurements, the patients will be restricted to a liquid diet to minimize the stasis of food in the oesophagus. Study subjects will arrive in the morning at the AIG hospital after an overnight fast, with no intake of fluid after midnight except water. If this is not possible, the medication should, of course, be ingested before the measurements. Before the first measurements, patients must have been fasting for four hours, so also no intake of water. UGI endoscopy followed by High-resolution oesophageal manometry later timed barium esophagogram will be done.

The formal investigation for patients with reflux symptoms after one month will be UGI endoscopy, High-resolution oesophageal manometry and 24-hour ambulatory pH-impedance monitoring. Study subjects go home with the pH-impedance catheter in place and will receive a diary to write down their symptoms. During this measurement, the study subject has to drink and eat at everyday moments. Still, there is no restriction concerning the food intake, except again an overnight fast due to the timed barium oesophagography the next day. The following day patients come back to the hospital where the pH-impedance catheter will be removed, and a timed barium oesophagography will be performed, which is the last measurement.

5f. METHODS OF ASSESSMENT-

A)High-Resolution Manometry (HRM)

A water-perfused high-resolution manometry assembly with 21 water-perfused sensors spaced at 1-cm intervals at the position of the esophagogastric junction will be used.

Each sensor is accurate to within 1mmHg, capable of recording transient pressure changes over 6000 mmHg/s, and zeroed to atmospheric pressure. The high-resolution manometry assembly will be introduced transnasal and positioned to record from hypopharynx to stomach with about five intragastric sensors. Data are analyzed using Solar high-resolution manometry software (Medical Measurement Systems, Enschede, The Netherlands).

  1. pH- impedance monitoring

A pH-impedance catheter will be introduced transnasally. A 2.1-mm outer diameter study catheter comprised of six electrode pairs measuring intraluminal impedance at 3, 5, 7, 9, 15 and 17 cm above the LES and an ISFET pH sensor, placed 5 cm above the LES will be used. Before and after recording the pH electrode will be calibrated using standard buffers of pH seven and pH 1. The catheter will be positioned in such a way that the pH sensor is located 5 cm above the LES, which is based on manometry readings.

  1. Analysis of the data of the HRM and pH-impedance monitoring

For analysis of the data obtained with HRM and pH-impedance measurement, MMS software (Enschede, The Netherlands) Will be used.The HRM will give insight into the esophageal function. It provides information on the contractile activity of the oesophagal body and the esophagogastric junction, including the LES. Therefore it helps distinguish transient LES relaxation (TLESRs), which occurs in GERD, from pseudo relaxation of the LES by shortening the oesophagal body. pH impedance monitoring provides information on oesophagal bolus transit. GER is characterized by TLESRs and a retrograde moving decrease in impedance with an abrupt drop in pH levels followed by normalization of the impedance and pH. In the case of fermentation, there is a slight and longer decrease in impedance and pH. The pH-impedance monitoring will also record all reflux episodes, both acid as non-acid, during the 24-hours measurement. During the analysis of the data of the pH-impedance monitoring, reflux symptoms will be correlated with acid and non-acid reflux episodes. A positive correlation is declared if a specific reflux symptom is preceded by a reflux episode within two minutes. The analysis will be done manually for all the patients as the risk of false-positive is more with the automated analysis. Oesophageal acidification patterns observed during pH-impedance monitoring.

  1. Acid reflux with average clearance: rapid pH drop to below 4, drop rate ≥one pH unit per second, lasting between 10 s and 5 min.
  2. Acid reflux with delayed clearance: rapid pH drop to below 4, drop rate≥one pH unit per second, lasting longer than 5 min.
  3. Acid fermentation: slow pH drop to below 4, drop rate <1 pH unit per minute, prevailing longer than 5 min most specific for achalasia cardia. Automated analysis can count these refluxes as false positive and can misdiagnose fermentation as reflux after POEM.
  4. Stasis of recently ingested acidic food or drink: pH drops to below four during meal/drink, pH below 4 persisting longer than 5 min after meal/drink.
  5. Unclassified: pH drop below 4, not meeting criteria for any of the acid patterns described above.
  6. Timed barium esophagram

A maximal tolerable amount of low-density barium sulphate must be ingested by the study subjects in 30-45 s without regurgitation or aspiration. After ingestion of low-density barium sulphate, oesophageal stasis will be determined at 1, 2 and 5 minutes with the study subject upright in a slight left posterior position. The distance from the tapered distal oesophagus to the top of the barium column and the maximal diameter of the oesophagus is measured.

  1. Questionnaires
  • Eckardt score, which is the sum of symptom scores for dysphagia, regurgitation, chest pain, and weight loss. Each symptom is scored from 0 to 3. The minimum score is 0, and the maximum score is 12. Pre and post values will be recorded.
  • The validated Achalasia Disease-Specific Quality-of-Life questionnaire (Achalasia- DSQoL). Pre and post POEM values will be recorded.
  • The validated Gastroesophageal Reflux Disease Questionnaire (GERDQ) is a self-assessment questionnaire that can be used for the diagnosis and follow-up of gastroesophageal reflux disease. It measures both symptoms and the impact of symptoms on a person's daily life. 5g. STOPPING OR DISCONTINUATION CRITERIA- NOT APPLICABLE
  1. OUTCOME MEASURES Three-month post peroral endoscopic myotomy
  2. SAMPLE SIZE CALCULATION- Sample size- 50 patients Expected outcomes - 18- 28 per cent is likely to be symptomatic post POEM surgery, and true reflux incidence maybe around 5- 10 per cent. Considering incidence for GERD population from south India, around 8 per cent sample size will be about 50, with the study's power as 80 per cent, with 95 per cent confidence interval and 5 per cent margin of error.
  3. STATISTICAL ANALYSIS- Data will be expressed as median and percentile values (5th, 25th, 75th and 95th percentiles). Depending on the normality of distribution, we will use either paired Student's t-test or Mann-Whitney U test for paired comparison. Likewise, we will use a one-way analysis of variance with Tukey test or Kruskal-Wallis, followed by Dunn's test as appropriate. The upper limit of normal will be defined as the 95th percentile of expected values. For PSPW index and MNBI thresholds, we will use the 5th and 25th percentile values. P≤0.05 will be considered statistically significant.
  4. ETHICAL JUSTIFICATION OF THE STUDY All patients of Achalasia patients who undergo palliative treatment in the form of peroral endoscopic measurement will be tested after the procedure at 3 months. It will give us insight into the true incidence of GERD and also will determine their therapy based on the phenotype they fit in.
Being tested
Peroral endoscopic myotomy
Keywords
Achalasia cardia, Peroral endoscopic myotomy, Gastroesophageal Reflux, oesophageal pH study, oesophageal acidification, High resolution manometry
Medical subject headings
Esophageal Achalasia, Gastroesophageal Reflux

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Peroral endoscopic myotomyProcedure or surgery

    Peroral endoscopic myotomy involves an initial incision on the internal lining of the oesophagus. This permits entry of the endoscope to within the wall of the oesophagus, where the muscle will be exposed. The inner layer of the muscle near the lower oesophagal sphincter will be cut (this is termed myotomy). At the conclusion of the procedure, the oesophagal incision will be closed with standard endoscopic clips.

Study groups in NCT04951739
Study groupRoleWhat they receive
Achalasia cardia patients - post peroral endoscopic myotomyAll the patients who will undergo peroral endoscopic myotomy for the treatment of achalasia cardia patients.
Receives: Procedure: Peroral endoscopic myotomy

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. To Investigate the incidence of reflux in patients after peroral endoscopic myotomy in achalasia cardia patients.

    To study the incidence of true reflux in patients with achalasia cardia who have undergone peroral endoscopic myotomy with 24 hour ambulatory pH monitoring.

    Measured: Three months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted7 Jul 2021
  2. Study start1 Jul 2021
  3. Primary completion15 Dec 2021
  4. Study completion15 Mar 2022

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
64 participants (actual)
Target duration
3 Months
IDs, dates and publications
ClinicalTrials.gov ID
NCT04951739
Sponsor's protocol ID
AIG/IEC-BH&R 13/05.2021-01
Status last verified
Jan 2023
First submitted
1 Jun 2021
Last updated
31 Jan 2023
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No

Publications

  • Boeckxstaens GE. The lower oesophageal sphincter. Neurogastroenterol Motil. 2005 Jun;17 Suppl 1:13-21. doi: 10.1111/j.1365-2982.2005.00661.x.

    PubMed 15836451
  • Campos GM, Vittinghoff E, Rabl C, Takata M, Gadenstatter M, Lin F, Ciovica R. Endoscopic and surgical treatments for achalasia: a systematic review and meta-analysis. Ann Surg. 2009 Jan;249(1):45-57. doi: 10.1097/SLA.0b013e31818e43ab.

    PubMed 19106675
  • Lopushinsky SR, Urbach DR. Pneumatic dilatation and surgical myotomy for achalasia. JAMA. 2006 Nov 8;296(18):2227-33. doi: 10.1001/jama.296.18.2227.

    PubMed 17090769
  • Anderson SH, Yadegarfar G, Arastu MH, Anggiansah R, Anggiansah A. The relationship between gastro-oesophageal reflux symptoms and achalasia. Eur J Gastroenterol Hepatol. 2006 Apr;18(4):369-74. doi: 10.1097/00042737-200604000-00009.

    PubMed 16538107
  • Crookes PF, Corkill S, DeMeester TR. Gastroesophageal reflux in achalasia. When is reflux really reflux? Dig Dis Sci. 1997 Jul;42(7):1354-61. doi: 10.1023/a:1018873501205.

    PubMed 9246028
  • van Herwaarden MA, Samsom M, Smout AJ. Prolonged manometric recordings of oesophagus and lower oesophageal sphincter in achalasia patients. Gut. 2001 Dec;49(6):813-21. doi: 10.1136/gut.49.6.813.

    PubMed 11709516
  • Shoenut JP, Micflikier AB, Yaffe CS, Den Boer B, Teskey JM. Reflux in untreated achalasia patients. J Clin Gastroenterol. 1995 Jan;20(1):6-11. doi: 10.1097/00004836-199501000-00004.

    PubMed 7884182
  • Katzka DA, Sidhu M, Castell DO. Hypertensive lower esophageal sphincter pressures and gastroesophageal reflux: an apparent paradox that is not unusual. Am J Gastroenterol. 1995 Feb;90(2):280-4.

    PubMed 7847301
  • Novais PA, Lemme EM. 24-h pH monitoring patterns and clinical response after achalasia treatment with pneumatic dilation or laparoscopic Heller myotomy. Aliment Pharmacol Ther. 2010 Nov;32(10):1257-65. doi: 10.1111/j.1365-2036.2010.04461.x. Epub 2010 Sep 25.

    PubMed 20955445
  • Shoenut JP, Duerksen D, Yaffe CS. A prospective assessment of gastroesophageal reflux before and after treatment of achalasia patients: pneumatic dilation versus transthoracic limited myotomy. Am J Gastroenterol. 1997 Jul;92(7):1109-12.

    PubMed 9219779
  • Spechler SJ, Souza RF, Rosenberg SJ, Ruben RA, Goyal RK. Heartburn in patients with achalasia. Gut. 1995 Sep;37(3):305-8. doi: 10.1136/gut.37.3.305.

    PubMed 7590421
  • Eckardt VF, Aignherr C, Bernhard G. Predictors of outcome in patients with achalasia treated by pneumatic dilation. Gastroenterology. 1992 Dec;103(6):1732-8. doi: 10.1016/0016-5085(92)91428-7.

    PubMed 1451966
  • Rohof WO, Hirsch DP, Kessing BF, Boeckxstaens GE. Efficacy of treatment for patients with achalasia depends on the distensibility of the esophagogastric junction. Gastroenterology. 2012 Aug;143(2):328-35. doi: 10.1053/j.gastro.2012.04.048. Epub 2012 May 2.

    PubMed 22562023
  • Rohof WO, Lei A, Boeckxstaens GE. Esophageal stasis on a timed barium esophagogram predicts recurrent symptoms in patients with long-standing achalasia. Am J Gastroenterol. 2013 Jan;108(1):49-55. doi: 10.1038/ajg.2012.318. Epub 2012 Sep 25.

    PubMed 23007004
  • Vaezi MF, Baker ME, Achkar E, Richter JE. Timed barium oesophagram: better predictor of long term success after pneumatic dilation in achalasia than symptom assessment. Gut. 2002 Jun;50(6):765-70. doi: 10.1136/gut.50.6.765.

    PubMed 12010876

Questions about this trial

What is this clinical trial studying?

An observational study of Achalasia Cardia and Gastroesophageal Reflux, run by Asian Institute of Gastroenterology, India at 1 site in India.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 17 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 31 Jan 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in India. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

To Investigate the incidence of reflux in patients after peroral endoscopic myotomy in achalasia cardia patients. (time frame: Three months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04951739, which also lists 18 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 31 Jan 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in